MiMedx Group (MDXG) Projected to Post Earnings on Wednesday

MiMedx Group (NASDAQ:MDXG - Get Free Report) will likely be posting its Q2 2025 quarterly earnings results after the market closes on Wednesday, July 30th. Analysts expect the company to announce earnings of $0.06 per share and revenue of $90.79 million for the quarter.

MiMedx Group (NASDAQ:MDXG - Get Free Report) last announced its quarterly earnings data on Wednesday, April 30th. The company reported $0.06 earnings per share (EPS) for the quarter, meeting analysts' consensus estimates of $0.06. MiMedx Group had a net margin of 11.40% and a return on equity of 22.70%. The firm had revenue of $88.21 million during the quarter, compared to analyst estimates of $86.32 million. On average, analysts expect MiMedx Group to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

MiMedx Group Trading Down 1.2%

MiMedx Group stock traded down $0.08 during midday trading on Friday, hitting $6.77. 557,682 shares of the stock were exchanged, compared to its average volume of 935,538. The company has a current ratio of 4.70, a quick ratio of 4.13 and a debt-to-equity ratio of 0.09. The stock's 50-day simple moving average is $6.45 and its 200 day simple moving average is $7.32. MiMedx Group has a fifty-two week low of $5.47 and a fifty-two week high of $10.14. The stock has a market capitalization of $999.93 million, a price-to-earnings ratio of 25.07 and a beta of 1.76.

Insiders Place Their Bets

In other news, CEO Joseph H. Capper bought 200,000 shares of the business's stock in a transaction on Friday, May 2nd. The shares were bought at an average price of $6.34 per share, with a total value of $1,268,000.00. Following the completion of the transaction, the chief executive officer directly owned 529,530 shares in the company, valued at $3,357,220.20. This trade represents a 60.69% increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Company insiders own 1.70% of the company's stock.

Institutional Investors Weigh In On MiMedx Group

Several institutional investors and hedge funds have recently modified their holdings of the company. Millennium Management LLC boosted its holdings in MiMedx Group by 93.9% during the 1st quarter. Millennium Management LLC now owns 1,230,984 shares of the company's stock valued at $9,355,000 after acquiring an additional 596,016 shares during the period. Goldman Sachs Group Inc. lifted its position in shares of MiMedx Group by 22.7% during the first quarter. Goldman Sachs Group Inc. now owns 1,121,814 shares of the company's stock worth $8,526,000 after purchasing an additional 207,397 shares in the last quarter. Royal Bank of Canada boosted its stake in shares of MiMedx Group by 1.4% in the first quarter. Royal Bank of Canada now owns 982,532 shares of the company's stock valued at $7,466,000 after purchasing an additional 13,629 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its holdings in shares of MiMedx Group by 5.8% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 73,518 shares of the company's stock valued at $559,000 after purchasing an additional 4,049 shares in the last quarter. Finally, Jacobs Levy Equity Management Inc. acquired a new position in shares of MiMedx Group in the first quarter valued at approximately $232,000. Hedge funds and other institutional investors own 79.15% of the company's stock.

Analyst Upgrades and Downgrades

A number of research analysts recently commented on MDXG shares. Cantor Fitzgerald reiterated an "overweight" rating and issued a $11.00 price objective on shares of MiMedx Group in a report on Tuesday, July 15th. Wall Street Zen lowered MiMedx Group from a "buy" rating to a "hold" rating in a research note on Friday, July 18th.

About MiMedx Group

MiMedx Group, Inc develops and distributes placental tissue allografts for various sectors of healthcare. It processes the human placental tissues utilizing its patented and proprietary PURION process to produce allografts that retains the tissue's inherent biological properties and regulatory proteins.